Seek Returns

Incyte (INCY) Stock Analysis

This is a peer-relative look at Incyte (INCY): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.

Company Profile

Company profile fields for Incyte (INCY)
Profile ItemINCY
NameIncyte Corp.
Country/RegionUnited States
GICS SectorHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
GICS Sub-IndustryBiotechnology
Market Capitalization24.39 billion USD
CurrencyUSD
ExchangeNasdaq
Listing DateNovember 4, 1993
Security TypeCommon Stock

Price Performance

Cumulative Growth

INCY
GSPC
Loading price history…
Incyte (INCY) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Incyte (INCY) and S&P 500 (GSPC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Incyte (INCY) and S&P 500 (GSPC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Incyte (INCY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: INCYIndustry group median
Total Return (1Y)14.06%24.62%
Total Return (3Y, Annualized)32.03%20.37%
Total Return (5Y, Annualized)12.69%-4.02%

Risk Profile

Drawdown History

INCY
GSPC
Loading price history…
Incyte (INCY) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Incyte (INCY) and S&P 500 (GSPC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Incyte (INCY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: INCYIndustry group median
Volatility (1Y, Annualized)33.19%66.36%
Beta (5Y)0.780.93
Max Drawdown (5Y)-40.50%-80.19%

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
Each dot is a stock plotted by 1-year volatility (risk) and 1-year return. INCY is highlighted; the dashed line is the Capital Allocation Line from the risk-free rate through the industry median — dots above it are stronger on a risk-adjusted basis.

Risk-Adjusted Metrics

Incyte (INCY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: INCYIndustry group median
Sharpe Ratio (1Y)0.290.36
Sortino Ratio (1Y)0.460.58

Profitability

ROE (TTM)

Incyte (INCY) posts ROE of 7.84%, in the upper peer quartile. That suggests the company earns more from each dollar of shareholders’ equity than most industry peers, a useful capital-efficiency signal.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.84%

Group distribution
Max
109.18%
INCY
7.84%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Largest peers
LLY
86.02%
NVS
24.33%
AZN
22.57%
JNJ
20.02%
INCY
7.84%
MRK
5.06%
ABBV
--
Loading chart…
Where Incyte (INCY) stands on ROE within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Net Margin (TTM)

Incyte (INCY) keeps 6.71% of revenue as net profit, putting net margin in the upper peer quartile. After operating costs, interest, and taxes, more of each sales dollar reaches shareholders than it does at most industry peers.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.71%

Group distribution
Max
18.05%
INCY
6.71%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Largest peers
LLY
31.90%
AZN
17.68%
NVS
17.49%
JNJ
16.20%
ABBV
15.67%
INCY
6.71%
MRK
3.64%
Loading chart…
Where Incyte (INCY) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Margin (TTM)

Incyte (INCY) turns 33.72% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.72%

Group distribution
Max
83.12%
INCY
33.72%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Largest peers
LLY
53.66%
ABBV
39.59%
MRK
35.22%
NVS
34.27%
INCY
33.72%
AZN
29.57%
JNJ
25.74%
Loading chart…
Where Incyte (INCY) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability Metrics

Incyte (INCY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: INCYIndustry group median
ROE (TTM)7.84%-26.66%
ROA (TTM)17.78%-12.50%
Net Margin (TTM)6.71%0.00%
Operating Margin (TTM)33.72%0.00%
Gross Margin (TTM)56.02%37.87%

Growth

Revenue Growth

Incyte (INCY) grew revenue 21.22%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.

Loading chart…
Incyte (INCY): Revenue Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

EPS Growth

Incyte (INCY) grew earnings per share 4,173.33%, above the industry benchmark range. Profits are compounding faster than at any typical peer, though a depressed base year can inflate the percentage, so the level of earnings matters alongside the rate.

Loading chart…
Incyte (INCY): EPS Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

Growth Metrics

Incyte (INCY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: INCYIndustry group median
Revenue Growth (YoY)21.22%11.45%
Revenue Growth (3Y CAGR)14.84%9.94%
EPS Growth (YoY)4,173.33%4.28%
EPS Growth (3Y CAGR)61.56%4.17%

Financial Strength

Current Ratio (MRQ)

Incyte (INCY) has current ratio of 3.84, in the healthier middle range for its industry. The short-term asset cushion looks balanced relative to peers rather than stretched thin.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.84

Group distribution
Max
25.13
Q3
12.13
Median
5.52
INCY
3.84
Q1
2.47
Min
0.10
Largest peers
INCY
3.84
LLY
1.39
MRK
1.35
JNJ
1.02
AZN
1.01
NVS
0.88
ABBV
0.87
Loading chart…
Where Incyte (INCY) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt / Equity (MRQ)

Incyte (INCY) has debt-to-equity ratio of 0.01, in the lower-leverage quartile for its industry. Borrowing is modest relative to equity compared with most peers, which can leave more flexibility through a cycle.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.01

Group distribution
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
INCY
0.01
Min
0.00
Largest peers
NVS
1.29
LLY
1.23
MRK
1.20
AZN
0.66
JNJ
0.55
INCY
0.01
ABBV
--
Loading chart…
Where Incyte (INCY) stands on debt-to-equity ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Financial Strength Metrics

Incyte (INCY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: INCYIndustry group median
Current Ratio (MRQ)3.845.52
Debt / Equity (MRQ)0.010.15
Net Debt / EBITDA-1.881.08

Dividends

Dividend Yield (TTM)

Incyte (INCY) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution
INCY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Largest peers
NVS
2.88%
ABBV
2.40%
MRK
2.29%
JNJ
1.94%
AZN
1.73%
LLY
0.49%
INCY
0.00%
Loading chart…
Where Incyte (INCY) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

Incyte (INCY) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution
INCY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Largest peers
MRK
343.43%
ABBV
117.35%
NVS
90.46%
JNJ
80.12%
AZN
45.38%
LLY
21.71%
INCY
0.00%
Loading chart…
Where Incyte (INCY) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Metrics

Incyte (INCY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: INCYIndustry group median
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Incyte (INCY) trades at P/E ratio of 61.05, in the richer earnings-multiple quartile for its industry. That premium needs support from growth, durable earnings, or stronger business quality.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

61.05

Group distribution
Max
85.34
INCY
61.05
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Largest peers
MRK
148.21
INCY
61.05
ABBV
50.05
LLY
43.95
JNJ
41.92
NVS
31.02
AZN
26.37
Loading chart…
Where Incyte (INCY) stands on P/E ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/S Ratio (TTM)

Incyte (INCY) trades at 4.06 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.06

Group distribution
Max
58.18
Q3
25.77
Median
7.30
INCY
4.06
Q1
3.01
Min
0.01
Largest peers
LLY
13.95
ABBV
7.80
JNJ
6.69
MRK
5.37
NVS
5.35
AZN
4.63
INCY
4.06
Loading chart…
Where Incyte (INCY) stands on P/S ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/B Ratio (MRQ)

Incyte (INCY) trades at 4.33 on P/B ratio, roughly in line with the industry’s normal price-to-book range. Its balance sheet is not being priced at a clear discount or premium versus peers.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.33

Group distribution
Max
13.53
Q3
6.54
INCY
4.33
Median
3.25
Q1
1.69
Min
-5.59
Largest peers
LLY
29.96
NVS
8.25
JNJ
8.16
MRK
8.06
AZN
5.59
INCY
4.33
ABBV
-112.34
Loading chart…
Where Incyte (INCY) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation Metrics

Incyte (INCY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: INCYIndustry group median
P/E Ratio (TTM)61.0526.69
P/S Ratio (TTM)4.067.30
P/B Ratio (MRQ)4.333.25
Free Cash Flow Yield (TTM)5.28%-1.66%